0001104659-24-059107.txt : 20240509 0001104659-24-059107.hdr.sgml : 20240509 20240509071313 ACCESSION NUMBER: 0001104659-24-059107 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Applied Therapeutics, Inc. CENTRAL INDEX KEY: 0001697532 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38898 FILM NUMBER: 24928542 BUSINESS ADDRESS: STREET 1: 545 FIFTH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-220-9226 MAIL ADDRESS: STREET 1: 545 FIFTH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: Applied Therapeutics Inc. DATE OF NAME CHANGE: 20170208 8-K 1 tm2413888d2_8k.htm FORM 8-K
false 0001697532 0001697532 2024-05-09 2024-05-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 9, 2024

 

APPLIED THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38898   81-3405262
(State or Other Jurisdiction of
Incorporation)		   (Commission File Number)   (I.R.S. Employer Identification No.)

 

545 Fifth Avenue, Suite 1400
New York, NY 10017		   10017
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code:  (212) 220-9226

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock   APLT   The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company               x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      x

 

 

 

 

 

 

Item 2.02.Results of Operations and Financial Condition.

 

On May [9], 2024, Applied Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information provided in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits:

     

The following exhibit is attached with this current report on Form 8-K:

 

Exhibit
No.

  

Description

   
99.1   Press Release, dated May 9, 2024.
104   Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the inline XBRL document.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  APPLIED THERAPEUTICS, INC.
     
Dated: May 9, 2024 By: /s/ Shoshana Shendelman
  Name: Shoshana Shendelman
  Title: President and Chief Executive Officer

 

 

 

 

 EX-99.1 2 tm2413888d2_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Applied Therapeutics Reports First Quarter 2024 Financial Results

 

-      Govorestat NDA for Classic Galactosemia under Priority Review, PDUFA target action date of November 28, 2024

 

-      Govorestat MAA under review by EMA; Day 120 3-month clock-stop extension granted; decision expected in early Q1 2025

 

-      Company discussing potential NDA submission under Accelerated Approval for govorestat for treatment of SORD Deficiency with Neurology I Division of FDA

 

NEW YORK, May 9, 2024 – Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the first quarter ended March 31, 2024.

 

“Preparations are underway for the potential approval and commercial launch of govorestat for the treatment of Classic Galactosemia in the US and EU, following the significant regulatory progress we have already made in 2024,” said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics. “We are also discussing a potential NDA submission for SORD Deficiency with the Neurology Division at FDA, further advancing our objective of bringing first ever treatment to patients with rare diseases.”

 

Recent Highlights

 

·Govorestat NDA Under Priority Review by US FDA for Treatment of Classic Galactosemia, PDUFA Target Action Date of November 28, 2024; MAA under CHMP Review by EMA. In March 2024, the Company announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia to allow more time to review supplemental analyses of previously submitted data that had been provided by Applied in response to the FDA’s routine information requests. No additional data or studies have been requested by the FDA at this time. The new PDUFA action date is November 28, 2024. The NDA was granted Priority Review Status, and the FDA also noted that it plans to hold an advisory committee meeting to discuss the application. Govorestat was previously granted Pediatric Rare Disease designation and will qualify for a Priority Review Voucher (PRV) upon approval. The Company has also submitted a Marketing Authorization Application (MAA) for govorestat for the treatment of Classic Galactosemia to the European Medicines Agency (EMA), which was validated in December 2023 and is under review by the EMA’s Committee for Medicinal Products for Human Use (CHMP). In April 2024, the EMA granted a 3-month extension to the Day 120 clock stop period to allow sufficient time for responses to the CHMP’s Day 120 list of questions. As a result, the Company now expects a decision by the EMA in early first quarter of 2025. The NDA and MAA submission packages include clinical outcomes data from the Phase 3 registrational ACTION-Galactosemia Kids study in children aged 2-17 with Galactosemia, the Phase 1/2 ACTION-Galactosemia study in adult patients with Galactosemia, and preclinical data.

 

 

 

 

·Appointed Dale Hooks as Chief Commercial Officer. In April 2024, the Company appointed Dale Hooks as Chief Commercial Officer to lead Applied’s commercial preparations for the potential launch of govorestat for the treatment of Classic Galactosemia and SORD. Mr. Hooks brings over 30 years of biopharmaceutical experience in leadership, rare disease marketing and sales roles to Applied Therapeutics.

 

·Presented Full Results from Phase 3 ARISE-HF Study of AT-001 (caficrestat) in Diabetic Cardiomyopathy at the 2024 American College of Cardiology Annual Scientific Session. In April 2024, the Company presented full results from the Phase 3 ARISE-HF study of AT-001 in patients with diabetic cardiomyopathy (DbCM) in an oral presentation at the 2024 American College of Cardiology (ACC) Annual Scientific Session. In the ARISE-HF study, treatment with AT-001 demonstrated a strong trend in stabilizing cardiac functional capacity, and a statistically significant difference in cardiac functional capacity in a prespecified subgroup of patients not receiving concomitant treatment with an SGLT2 or GLP-1 while preventing clinically significant worsening. Furthermore, AT-001 treatment prevented progression to overt heart failure in patients with DbCM as compared to placebo (p=0.0285). Data also demonstrated that AT-001 was safe and well tolerated in a large cohort of patients, providing proof of concept that the technology has overcome the selectivity and safety issues of “old” aldose reductase inhibitors. Following the presentation, the full study results were published in the Journal of the American College of Cardiology (JACC).

 

Financial Results

 

·Cash and cash equivalents and short-term investments totaled $146.5 million as of March 31, 2024, compared with $49.9 million at December 31, 2023.

 

·Research and development expenses for the three months ended March 31, 2024, were $12.2 million, compared to $15.9 million for the three months ended March 31, 2023. The decrease of approximately $3.7 million was primarily attributed to decreased expenses related to contract research organizations (CROs) and drug manufacturing and formulation costs, partially offset by an increase in regulatory and personnel expenses.

 

·General and administrative expenses were $9.1 million for the three months ended March 31, 2024, compared to $5.6 million for the three months ended March 31, 2023. The increase of approximately $3.5 million was primarily related to an increase in legal and professional fees of $1.2 million and $1.4 million in commercial expenses to support planned commercialization of govorestat, and an increase in other expenses of $0.9 million due to an overall increase in data storage costs to support planned commercialization.

 

·Net loss for the first quarter of 2024 was $83.9 million, or $0.67 per basic and diluted common share, compared to a net loss of $10.1 million, or $0.18 per basic and diluted common share, for the first quarter 2023.

 

·Cash runway: The Company expects that its cash and cash equivalents will fund the business into 2026. Additionally, the sale of the priority review voucher (PRV), which would be granted upon a potential NDA approval of govorestat for the treatment of Galactosemia could substantially extend the Company’s cash runway.

 

 

 

 

About Applied Therapeutics

 

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

 

To learn more, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding the strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “plan,” “intend,” “predicts” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding the (i) Company’s expectation that its cash and cash equivalents will fund the business into 2026; (ii) the likelihood that the Company’s ongoing NDA and MMA submissions will be approved and the timing of any approval decision and (iii) statements related to the potential commercial launch of govorestat. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved.

 

Such risks and uncertainties include, without limitation, (i) our plans to develop, market and commercialize our product candidates, (ii) the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs, (iii) our ability to take advantage of expedited regulatory pathways for any of our product candidates, (iv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing, (v) our ability to successfully acquire or license additional product candidates on reasonable terms and advance product candidates into, and successfully complete, clinical studies, (vi) our ability to maintain and establish collaborations or obtain additional funding, (vii) our ability to obtain and timing of regulatory approval of our current and future product candidates, (viii) the anticipated indications for our product candidates, if approved, (ix) our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates, (x) our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources, (xi) the implementation of our business model and strategic plans for our business and product candidates, (xii) our intellectual property position and the duration of our patent rights, (xiii) developments or disputes concerning our intellectual property or other proprietary rights, (xiv) our expectations regarding government and third-party payor coverage and reimbursement, (xv) our ability to compete in the markets we serve, (xvi) the impact of government laws and regulations and liabilities thereunder, (xvii) developments relating to our competitors and our industry, (xviii) our ability to achieve the anticipated benefits from the agreements entered into in connection with our partnership with Advanz Pharma and (xiv) other factors that may impact our financial results. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

 

Contacts

 

Investors:

Maeve Conneighton

(212) 600-1902 or

appliedtherapeutics@argotpartners.com

 

Media:

media@appliedtherapeutics.com

 

 

 

 

Applied Therapeutics, Inc.

Condensed Balance Sheets

(in thousands, except share and per share data)

(Unaudited)

 

   As of   As of 
   March 31,   December 31, 
   2024   2023 
ASSETS          
CURRENT ASSETS:          
Cash and cash equivalents  $146,484   $49,898 
Security deposits and leasehold improvements   253    254 
Prepaid expenses and other current assets   4,169    4,234 
Total current assets   150,906    54,386 
Operating lease right-of-use asset   328    447 
TOTAL ASSETS  $151,234   $54,833 
LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT)          
CURRENT LIABILITIES:          
Current portion of operating lease liabilities  $308   $429 
Accounts payable   4,019    1,742 
Accrued expenses and other current liabilities   14,641    15,286 
Warrant liabilities   64,937    53,725 
Total current liabilities   83,905    71,182 
NONCURRENT LIABILITIES:          
Noncurrent portion of operating lease liabilities   35    38 
Clinical holdback - long-term portion   —    759 
Total noncurrent liabilities   35    797 
Total liabilities   83,940    71,979 
STOCKHOLDERS’ EQUITY/(DEFICIT):          
Common stock, $0.0001 par value; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 114,241,803 shares issued and outstanding as of March 31, 2024 and 84,869,832 shares issued and outstanding as of December 31, 2023   11    8 
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of  March 31, 2024 and December 31, 2023   —    — 
Additional paid-in capital   619,807    451,432 
Accumulated deficit   (552,524)   (468,586)
Total stockholders' equity/(deficit)   67,294    (17,146)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT)  $151,234   $54,833 

 

 

 

 

Applied Therapeutics, Inc.

Condensed Statements of Operations

(in thousands, except share and per share data)

(Unaudited)

 

   Three Months Ended 
   March 31, 
   2024   2023 
REVENUE:        
License revenue  $—   $10,660 
Research and development services revenue   190    — 
Total revenue   190    10,660 
COSTS AND EXPENSES:          
Research and development   12,217    15,935 
General and administrative   9,066    5,583 
Total costs and expenses   21,283    21,518 
LOSS FROM OPERATIONS   (21,093)   (10,858)
OTHER (EXPENSE) INCOME, NET:          
Interest income   586    221 
Change in fair value of warrant liabilities   (63,405)   469 
Other expense   (26)   31 
Total other (expense) income, net   (62,845)   721 
Net loss  $(83,938)  $(10,137)
Net loss per share attributable to common stockholders—basic and diluted  $(0.67)  $(0.18)
Weighted-average common stock outstanding—basic and diluted   125,318,993    56,357,983 

 

 

 

 EX-101.SCH 3 aplt-20240509.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 aplt-20240509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 aplt-20240509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2413888d2_ex99-1img001.jpg GRAPHIC begin 644 tm2413888d2_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
May 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 09, 2024
Entity File Number 001-38898
Entity Registrant Name APPLIED THERAPEUTICS, INC.
Entity Central Index Key 0001697532
Entity Tax Identification Number 81-3405262
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 545 Fifth Avenue
Entity Address, Address Line Two Suite 1400
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10017
City Area Code 212
Local Phone Number 220-9226
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol APLT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://appliedtherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports aplt-20240509.xsd aplt-20240509_lab.xml aplt-20240509_pre.xml tm2413888d2_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2413888d2_8k.htm": { "nsprefix": "APLT", "nsuri": "http://appliedtherapeutics.com/20240509", "dts": { "schema": { "local": [ "aplt-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "aplt-20240509_lab.xml" ] }, "presentationLink": { "local": [ "aplt-20240509_pre.xml" ] }, "inline": { "local": [ "tm2413888d2_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://appliedtherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2413888d2_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2413888d2_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://appliedtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-059107-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-059107-xbrl.zip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end XML 18 tm2413888d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001697532 2024-05-09 2024-05-09 iso4217:USD shares iso4217:USD shares false 0001697532 8-K 2024-05-09 APPLIED THERAPEUTICS, INC. DE 001-38898 81-3405262 545 Fifth Avenue Suite 1400 New York NY 10017 212 220-9226 false false false false Common Stock APLT NASDAQ true true